Kopran Limited Schedules Stakeholder Meetings for Merger Approval with Kopran Laboratories

Kopran Limited has announced a series of stakeholder meetings scheduled for June 3, 2026, to consider and approve the proposed merger scheme with Kopran Laboratories Limited. The meetings are being convened pursuant to an order dated April 9, 2026, from the National Company Law Tribunal, Mumbai Bench.

Meeting Schedule and Structure

The company has organized six separate meetings for different stakeholder categories of both entities involved in the merger. All meetings will be conducted through video conferencing and other audio-visual means.

Company: Stakeholder Category: Date: Time (IST): Kopran Limited Equity Shareholders June 3, 2026 10.00 a.m. Kopran Limited Secured Creditors June 3, 2026 11.30 a.m. Kopran Limited Unsecured Creditors June 3, 2026 1.00 p.m. Kopran Laboratories Limited Equity Shareholders June 3, 2026 2.30 p.m. Kopran Laboratories Limited Secured Creditors June 3, 2026 3.30 p.m. Kopran Laboratories Limited Unsecured Creditors June 3, 2026 5.00 p.m.

Merger Details

The proposed transaction involves a scheme of amalgamation through merger by absorption, where Kopran Laboratories Limited will serve as the transferor company and Kopran Limited as the transferee company. The scheme is being implemented under Sections 230 to 232 of the Companies Act, 2013, and other applicable provisions.

Communication and Documentation

The company announced on April 30, 2026, that notices are being dispatched electronically to shareholders and creditors whose email addresses are registered with the company, share transfer agent, or depository participant. Physical copies will be sent to those whose email addresses are not registered.

Regulatory Compliance

The announcement has been made under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015. Complete meeting notices, explanatory statements, and annexures are available on the company's website at the dedicated amalgamation section.

The meetings represent a crucial step in the formal merger process, requiring approval from all stakeholder categories before the amalgamation can proceed under the regulatory framework.

Kopran Limited has received a significant regulatory milestone in its proposed merger process, with the National Company Law Tribunal (NCLT) Mumbai Bench directing the company to conduct mandatory stakeholder meetings. The development marks a crucial step forward in the pharmaceutical company's consolidation strategy.

NCLT Order Details

The Hon'ble NCLT Mumbai Bench issued its order on April 09, 2026, providing specific directions for the merger process. The tribunal has mandated Kopran Limited to organize separate meetings for different stakeholder categories as part of the amalgamation scheme.

Meeting Type: Stakeholder Category Equity Shareholders Meeting: All equity shareholders Secured Creditors Meeting: Secured creditors Unsecured Creditors Meeting: Unsecured creditors

Merger Scheme Overview

The proposed transaction involves the Scheme of Amalgamation through merger by absorption of Kopran Laboratories Limited (Transferor Company) with Kopran Limited (Transferee Company). The scheme was initially announced in the company's letter dated March 20, 2025, and operates under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013.

Parameter: Details Merger Type: Merger by Absorption Transferor Company: Kopran Laboratories Limited Transferee Company: Kopran Limited Legal Framework: Companies Act 2013, Sections 230-232 Status: Subject to regulatory approvals

Regulatory Compliance

The disclosure has been made in accordance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations. Company Secretary and Compliance Officer Sunil Sodhani signed the regulatory filing, ensuring compliance with stock exchange notification requirements.

Document Accessibility

The complete NCLT order is now publicly available on the company's official website at www.kopran.com . Stakeholders can access the detailed order through the dedicated link provided in the company's regulatory filing, ensuring transparency in the merger process.

The NCLT's direction represents a procedural advancement in the merger timeline, bringing the pharmaceutical company closer to completing its consolidation objectives. The mandated stakeholder meetings will provide the necessary forum for shareholders and creditors to review and approve the proposed amalgamation scheme.

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.

As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.